We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

280 hedge funds and large institutions have $934M invested in Intellia Therapeutics in 2025 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 111 increasing their positions, 87 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $18.2M | Put options by funds: $11.2M

30% more capital invested

Capital invested by funds: $720M → $934M (+$213M)

28% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 87

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.75% less ownership

Funds ownership: 97.84% → 96.1% (-1.7%)

5% less funds holding

Funds holding: 294 → 280 (-14)

21% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 53

Holders
280
Holders Change
-14
Holders Change %
-4.76%
% of All Funds
3.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
42
Increased
111
Reduced
87
Closed
53
Calls
$18.2M
Puts
$11.2M
Net Calls
+$7M
Net Calls Change
+$6.39M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$16.7M
2
WP
Woodline Partners
California
+$9.81M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$6.51M
4
Renaissance Technologies
Renaissance Technologies
New York
+$5.56M
5
MG
Marex Group
+$5.12M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$26.9M
2
Citadel Advisors
Citadel Advisors
Florida
-$16.8M
3
CC
Casdin Capital
New York
-$14.2M
4
BlackRock
BlackRock
New York
-$4.34M
5
Bank of America
Bank of America
North Carolina
-$4.24M
Name Holding Trade Value Shares
Change 		Change in
Stake
PWM
301
Prosperity Wealth Management
California
– -$169K -23,700 Closed
PCM
302
Polymer Capital Management
New York
– -$108K -15,230 Closed
Wealth Enhancement Advisory Services
303
Wealth Enhancement Advisory Services
Minnesota
– -$98K -13,789 Closed
SP
304
SIH Partners
Delaware
– -$95.3K -13,406 Closed
Franklin Resources
305
Franklin Resources
California
– -$90.7K -12,751 Closed
TCM
306
Teza Capital Management
Illinois
– -$83.1K -11,683 Closed
IC
307
IEQ Capital
California
– -$81.6K -11,473 Closed
SC
308
SummitTX Capital
Texas
– -$80K -11,258 Closed
4WM
309
49 Wealth Management
Texas
– -$74.1K -10,427 Closed
AF
310
Advisornet Financial
Minnesota
– -$71.7K -10,085 Closed
CF
311
Cantor Fitzgerald
New York
– -$71.1K -10,000 Closed
CI Investments Inc
312
CI Investments Inc
Ontario, Canada
– -$64K -8,953 Closed
CIAM
313
Caitong International Asset Management
Hong Kong
– -$56.1K -7,892 Closed
QT
314
Quantbot Technologies
New York
– -$47.4K -6,663 Closed
ACM
315
Aster Capital Management
United Arab Emirates
– -$59.1K -5,859 Closed
Amundi
316
Amundi
France
– -$34.9K -5,065 Closed
QCG
317
Quadrant Capital Group
Ohio
– -$17.9K -2,520 Closed
RF
318
Roxbury Financial
New Jersey
– -$10.1K -1,000 Closed
SFGP
319
Stonebridge Financial Group (Pennsylvania)
Pennsylvania
– -$7.11K -1,000 Closed
WPWM
320
Western Pacific Wealth Management
Illinois
– -$3.56K -500 Closed
IWP
321
IAG Wealth Partners
Wisconsin
– -$3.41K -480 Closed
CCM
322
Coldstream Capital Management
Washington
– -$3.12K -439 Closed
BIG
323
Brooklyn Investment Group
New York
– -$2.87K -404 Closed
PC
324
Promus Capital
Illinois
– -$2.85K -401 Closed
SW
325
SVB Wealth
Massachusetts
– -$1.35K -190 Closed
10 11 12
13
14

NTLA Hedge Fund Activity: Q2 2025 in Review

280 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2025, worth a combined $934M — up 30% from $720M a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of NTLA and 42 opened new positions — a net loss of 11 holders — while 87 trimmed existing stakes and 111 added.

The largest buyer was Baker Bros. Advisors, adding an estimated $16.7M. The largest seller was Capital International Investors, exiting entirely with an estimated $26.9M sold.

  • 280 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2025, down from 294 in Q1 2025.
  • Funds reported $934M of Intellia Therapeutics stock for Q2 2025, up 30% quarter-over-quarter.
  • 42 funds opened new Intellia Therapeutics positions in Q2 2025 and 53 closed out, a net change of -11 holders.
  • The largest Intellia Therapeutics buyer in Q2 2025 was Baker Bros. Advisors, an estimated $16.7M added.
  • The largest Intellia Therapeutics seller in Q2 2025 was Capital International Investors, an estimated $26.9M sold.

Based on aggregated 13F filings for Q2 2025.